Merck & Co's IMPROVE-IT hits its target
This article was originally published in Scrip
Executive Summary
The jury has been out for years, but the verdict is finally in: IMPROVE-IT has met its primary and all secondary composite endpoints. The news was released in a short statement from Merck & Co ahead of the full data presentation at the American Heart Association meeting in Chicago on 17 November.